Antibody-induced platelet activation - Potential impact on thromboembolic events in patients with antiphospholipid syndrome

Antibody-induced platelet activation - Potential impact on thromboembolic events in patients with antiphospholipid syndrome - APS-PCP-01

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039805

Enrollment

100

Registered

2026-04-01

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D68.6

Interventions

Group 1: Following consent during the routine blood draw: Collection of an additional serum tube (6 mL each)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - inpatient or outpatient patients with suspicion of APS - age 18 years or older

Exclusion criteria

Exclusion criteria: no consent

Design outcomes

Primary

Measure	Time frame
1. Prevalence of platelet-activating antibodies in a well-characterized cohort of patients with APS 2. Molecular mechanisms of APS antibody-induced platelet activation 3. Characterization of APS antibody-induced thrombus formation ex vivo	—

Secondary

Measure	Time frame
4. The role of platelet-leukocyte interactions in APS-antibody-induced thrombus formation	—

Countries

Germany

Contacts

Public ContactTamam Bakchoul

Institut für Klinische und Experimentelle Transfusionsmedizin Tübingen (IKET)

tamam.bakchoul@med.uni-tuebingen.de+4907071-2981602

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026